Valuation: LENZ Therapeutics, Inc.

Market Cap 156M 137M 126M 116M 220M 15.08B 223M 1.51B 593M 7.36B 588M 575M 25.42B P/E 2026 *
-1.11x
P/E 2027 * -1.46x
Enterprise Value 156M 137M 126M 116M 220M 15.08B 223M 1.51B 593M 7.36B 588M 575M 25.42B EV / Sales 2026 *
8.37x
EV / Sales 2027 * 2.48x
Free-Float
97.35%
Yield 2026 *
-
Yield 2027 * -
Change 5-day change 1-year change 3-year change Capi.($)
-2.75%-4.79% - - 156M
-3.42%+10.05%+58.59%+87.70% 57.82B
-0.05%-6.20%+55.97%+124.61% 53.71B
-2.14%-9.13%+2.74%+419.13% 23.8B
-0.47%-1.53%-18.61%-14.60% 23.26B
-0.56%+10.26%+44.03%-3.86% 20.7B
-0.29%-0.08%+38.91%-27.98% 17.81B
-4.55%-8.65%+194.32%+349.58% 16.9B
-2.61%+8.99%+46.11%+691.67% 16.36B
+0.23%-2.49%+24.26%+190.15% 13.96B
Average -1.66%+1.05%+49.59%+201.82% 27.15B
Weighted average by Cap. -1.62%+0.18%+49.14%+166.58%

Financials

2026 *2027 *
Net sales 18.7M 16.34M 15.11M 13.87M 26.25M 1.8B 26.71M 180M 70.81M 880M 70.22M 68.67M 3.04B 63.18M 55.23M 51.07M 46.87M 88.7M 6.09B 90.24M 609M 239M 2.97B 237M 232M 10.26B
Net income -142M -124M -114M -105M -199M -13.64B -202M -1.36B -536M -6.66B -532M -520M -23B -111M -96.79M -89.51M -82.14M -155M -10.67B -158M -1.07B -419M -5.21B -416M -407M -17.99B
Net Debt - -
Logo LENZ Therapeutics, Inc.
LENZ Therapeutics, Inc. is a pre-commercial stage biopharmaceutical company. The Company is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.
Employees
152
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB